Get started
Author

Huiqiang Huang

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2024 · Jeremy S Abramson, Matthew Ku, et al. · The Lancet · 181
PDF
Comparison of Quantitative and Qualitative Tests for Glucose-6-Phosphate Dehydrogenase Deficiency
2014 · Nicole LaRue, Maria Kahn, et al. · American Journal of Tropical Medicine and Hygiene · 111
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
2020 · Yi Ba, Yuankai Shi, et al. · Cancer Biology and Medicine · 96
First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: An updated analysis with long-term follow-up
2015 · LIANG WANG, ZHI-HUI WANG, et al. · Oncology Letters · 60
PDF
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study
2024 · Yan Gao, Haixia He, et al. · Signal Transduction and Targeted Therapy · 41
A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors
2007 · Xubin Lin, Huiqiang Huang, et al. · Cancer Biology & Therapy · 38
PDF
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
2023 · Yu-Qin Song, Hui-Lai Zhang, et al. · Haematologica · 18
PDF
Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy
2008 · Qingqing Cai, Huiqiang Huang, et al. · Expert Opinion on Pharmacotherapy · 14
Galectin-9 Facilitates Epstein-Barr Virus Latent Infection and Lymphomagenesis in Human B Cells
2023 · Jing-xiao Xu, Rong Zhang, et al. · Microbiology Spectrum · 13
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
2025 · Yan Gao, Yunhong Huang, et al. · Cancer · 12
PDF
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database
2023 · Xin Liu, Li-Ling Zhang, et al. · Haematologica · 11
PDF
Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 – IIB) cervical cancer: preliminary results of a single-institution experience
2011 · Xin Huang, Chunyan Lan, et al. · Expert Opinion on Pharmacotherapy · 10
Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
2023 · Yuqin Song, Shang-Ju Wu, et al. · Experimental Hematology and Oncology · 9
PDF
Ultrasensitive colorimetric immunoassay for aflatoxin B1 detection in lotus seed powder based on enhanced catalysis of Au@Pt with in situ deposition of PtNPs
2024 · Lei Zhang, Huiqiang Huang, et al. · Food Chemistry X · 8
CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma
2024 · Yali Wang, Jianfeng Chen, et al. · Cancer Letters · 8
First‐line immunotherapy with anti‐PD ‐1 antibody for extranodal NK/T ‐cell lymphoma: A retrospective study
2023 · Xiaoxiao Wang, Lei Wen, et al. · British Journal of Haematology · 8
Targeting P21-activated kinase suppresses proliferation and enhances chemosensitivity in T-cell lymphoblastic lymphoma
2023 · Ning Su, Yu Fang, et al. · Blood Science · 7
Survival Benefit of Adjuvant Radiation Therapy Following Asparaginase-Based Chemotherapy in Patients With Chemoresponsive Advanced-Stage Extranodal NK/T Cell Lymphoma: A Multicenter Study Using the China Lymphoma Collaborative Group Database
2025 · Ke Su, Xiao-Rong Hou, et al. · International Journal of Radiation Oncology*Biology*Physics · 4
Glofitamab Monotherapy Demonstrates High Complete Response Rates and Manageable Safety in Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies
2022 · Yu-Qin Song, Hui-Lai Zhang, et al. · Blood · 4
Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
2025 · Jeremy Abramson, Matthew Ku, et al. · Blood · 3
Optimized multiplex PCR-NGS for comprehensive HLA genotyping in Chinese populations: resolving ambiguities at high resolution
2025 · Cuello Garcia Haider, Binbin Sun, et al. · Frontiers in Immunology · 3
PDF
Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial
2025 · Yanyan Liu, Ningjing Lin, et al. · International Journal of Cancer · 3
PDF
Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial
2022 · Hui-Qiang Huang, Gao Yan, et al. · Blood · 3
Chinese expert consensus on the application of intravenous immunoglobulin in hematological diseases
2025 · Zhi Guo, Jie Zhu, et al. · Frontiers in Medicine · 2
PDF
Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study
2024 · Gareth P. Gregory, Jeremy S. Abramson, et al. · Blood · 2
Works count: 36
Citation count: 669
H-index: 10
I10-index: 12
Year
Topic
Type